EMA/CHMP backs bumper crop of new medicines for approval

13 December 2024

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended another batch medicines for approval at its December 2024 meeting, bringing the total number of medicines recommended for approval in 2024 to 114.

The CHMP recommended granting a marketing authorization for Andembry (garadacimab), from CSL Behring, for the prevention of recurrent attacks of hereditary angioedema, a rare, potentially life-threatening disorder characterized by attacks of cutaneous and submucosal swelling. BridgeBio

The committee adopted a positive opinion for Pharma’s (Nasdaq: BBIO) Beyonttra (acoramidis), for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy, a disease that affects the heart muscle.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK